Pharmacologic intravenous vitamin C is a multi-mechanistic, tumor-selective anti-cancer therapy that has been under-dosed, under-studied, and consistently underestimated. GlobalResearch.ca Nicolas Hulscher MPH | https://x.com/NicHulscher A major new review paper titled, High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges, analyzed 150+ studies and found that when vitamin C reaches true pharmacologic levels (20–30 mM), it behaves like a targeted, tumor-selective therapy — something past trials missed by under-dosing. The evidence base spans decades of laboratory, animal, and early-phase clinical research. The authors outline four major anti-cancer mechanisms of high-dose vitamin C — pro-oxidative tumor cytotoxicity, epigenetic reprogramming, suppression of oncogenic signaling pathways, and powerful immune activation. For a therapy this safe, inexpensive, and mechanistically potent, the findings are striking. Here’s what they …